Skip to content
Buy This GLP
← Research
Evidence

SURMOUNT-MAINTAIN: Full-Dose Tirzepatide, 5 mg or Placebo After 60 Weeks

After 60 weeks on tirzepatide, 378 adults were randomized to continue their maximum tolerated dose, drop to 5 mg or switch to placebo. Rescue tirzepatide was given to 8%, 25% and 67%, respectively, in the rescue analysis.

Editorial profile: Carla MedinaBuy This GLP Editorial Team7 min read
At week 112loss from baselinereceived rescuestayed on full dose21.9%8%dropped to 5 mg16.6%25%switched to placebo9.9%67%60 of 90 in the placebo analysis received rescue tirzepatide.

Who entered the maintenance phase?

Of the 441 adults who started open-label tirzepatide, 378 qualified for randomization at week 60. They had lost at least 5% of baseline weight and tolerated at least 10 mg. The trial assigned 140 to continue their maximum tolerated dose of 10 mg or 15 mg, 144 to reduce to 5 mg, and 94 to switch to placebo for another 52 weeks.[1]

The evidence on lower-dose GLP-1 maintenance depends on which patients enter a study. SURMOUNT-MAINTAIN selected adults who had already lost weight and tolerated a higher dose, so the results apply most directly to patients who meet those conditions.

Weight change and rescue treatment

At week 112, the model estimated weight loss from the original baseline at 21.9% (95% CI 20.3% to 23.5%) on the maximum tolerated dose, 16.6% (95% CI 15.1% to 18.0%) on 5 mg, and 9.9% (95% CI 8.8% to 11.1%) on placebo. Both tirzepatide groups had greater weight loss from baseline than placebo.[1]

From week 84, 24 weeks after randomization, the protocol allowed rescue tirzepatide if participants regained more than half the weight they had lost. In the rescue analysis, 11 of 138 (8%) at the maximum tolerated dose, 35 of 142 (25%) at 5 mg, and 60 of 90 (67%) on placebo received it.[1]

Safety and funding

Gastrointestinal symptoms were the most common adverse events with tirzepatide and occurred mainly during dose escalation. Eli Lilly funded the trial and took part in the design, data collection, analysis, and preparation of the report.[1]

Frequently asked

What happens if I stop after losing weight?
In the trial’s rescue analysis, 60 of 90 people switched to placebo received rescue tirzepatide, compared with 11 of 138 who continued their maximum tolerated dose.
Can I drop to a lower dose instead?
In this selected group, estimated weight loss from the original baseline was 16.6% on 5 mg, 21.9% at the maximum tolerated dose, and 9.9% on placebo at week 112. Discuss maintenance options with your prescriber.
Does this apply to everyone?
To enter the randomized maintenance phase, adults had to lose at least 5% of baseline weight during the lead-in and tolerate at least 10 mg of tirzepatide.

Sources

  1. [1] Horn DB, Aronne LJ, Wharton S, Bays HE, le Roux CW, Srinath R, et al. (2026). Tirzepatide for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN): a multicentre, double-blind, randomised, placebo-controlled trial The Lancet. PMID 42119587

Where to get it

Price the injectable sellers

The desk lists every seller that publishes an injectable figure, with the advertised price struck against the one a buyer is billed.

Open the price desk →

More in Evidence